Bharat Parenterals Q2 Results FY27: Revenue Up 110.89% to Rs 136.28 Cr, PAT Rs 11.82 Cr
- October 29, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Bharat Parenterals Q2 Results FY27 were declared on 29 October 2026, with consolidated revenue of Rs 136.28 Cr, up 110.89% from Rs 64.62 Cr a year earlier. Net profit was Rs 11.82 Cr against a loss of Rs 8.60 Cr in the same quarter last year. These quarterly results show YoY growth in revenue and in Operating Profit, which reached Rs 23.58 Cr. All figures are on a Consolidated basis.
Bharat Parenterals Ltd (BPLPHARMA) Q2 Results FY27 announced on 29 October 2026, covering the company’s financial performance for the July to September quarter. The results date brought revenue of Rs 136.28 Cr and PAT of Rs 11.82 Cr, and Bharat Parenterals Q2 Results FY27 are read here on a Consolidated basis against the year-ago quarter. These consolidated results frame everything that follows.
This Bharat Parenterals Q2 Results article covers the financial highlights, business drivers, outlook and risks, and the results analysis uses only the filed figures. Readers can follow later filings through the Univest Screener. The Financial Highlights come first.
Click Here – Get Free Investment Predictions
Bharat Parenterals Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 136.28 Cr | Rs 64.62 Cr | +110.89% YoY |
| Operating Profit | Rs 23.58 Cr | Rs 0.82 Cr | +2775.61% YoY |
| Net Profit (PAT) | Rs 11.82 Cr | Rs -8.6 Cr | +237.44% YoY |
Source: company filing for Bharat Parenterals Q2 Results FY27, 29 October 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Bharat Parenterals Q2 Results: What Stands Out
- Revenue of Rs 136.28 Cr: consolidated revenue rose 110.89% from Rs 64.62 Cr, more than double the year-ago quarter’s level.
- PAT of Rs 11.82 Cr: profit against a loss of Rs 8.60 Cr a year earlier, a swing of Rs 20.42 Cr.
- Operating Profit of Rs 23.58 Cr: up from Rs 0.82 Cr in the year-ago quarter, a rise of 2,775.61%.
- Margin of 8.7%: the profit margin moved from -13.3% in the comparison quarter, a shift Bharat Parenterals Q2 Results FY27 record in full.
- Next step: the performance analysis below places these four moves side by side for a closer read.
Bharat Parenterals Q2 Results FY27: Performance Analysis
Bharat Parenterals reported consolidated revenue of Rs 136.28 Cr and a profit of Rs 11.82 Cr for July to September 2026. Revenue grew 110.89% YoY from Rs 64.62 Cr, while PAT moved from a loss of Rs 8.60 Cr to a profit, a 237.44% change on the supplied figures. Together they define Bharat Parenterals Q2 Results FY27 at the headline level.
Operating Profit reached Rs 23.58 Cr against Rs 0.82 Cr a year earlier. On simple arithmetic that is 17.30% of revenue, compared with 1.27% in the year-ago quarter. This results analysis shows the YoY growth in Operating Profit running well ahead of the YoY growth in revenue, and Bharat Parenterals Q2 Results record both on one basis.
Investors following the quarterly results will next compare later disclosures with this base, since Rs 64.62 Cr of revenue and a loss of Rs 8.60 Cr set a low comparison point for Bharat Parenterals Q2 Results FY27. The numbers confirm what changed but not why, which is where the results analysis turns to the business factors.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue Growth – The results analysis points to three business factors, and the first is revenue, which grew 110.9% year on year to Rs 136.28 Cr in the latest quarter. That lifted the revenue line well above the Rs 64.62 Cr recorded in the comparison quarter.
Return to Profit – The company returned to a profit of Rs 11.82 Cr from a loss in the comparison quarter, and Bharat Parenterals Q2 Results FY27 place that change beside the revenue gain, so the profit line and the revenue line moved in the same direction.
Profit Margin – Profit margin improved to 8.7% from -13.3% in the comparison quarter. The quarterly results therefore show profit rising as a share of revenue, as well as in rupee terms, which leads into the FY27 outlook.
FY27 Outlook After Bharat Parenterals Q2 Results
FY27 full-year results will depend on the quarters still to be declared. This results analysis covers only the July to September 2026 quarter, in which net profit was Rs 11.82 Cr, so the full-year picture will form as later filings add to it, and Bharat Parenterals Q2 Results FY27 are one input among several.
Investors can compare each coming quarter with the Rs 136.28 Cr of revenue and Rs 23.58 Cr of Operating Profit recorded here, and the Univest Screener can be used to follow those filings. The risks below show what to weigh alongside that YoY growth.
Key Risks to Watch After Bharat Parenterals Q2 Results FY27
Low Return on Equity
YoY growth in revenue and profit sits beside a return on equity that was low at -8.36% in FY26. That full-year ratio shows the weaker base from which the latest Bharat Parenterals Q2 Results FY27 improved.
Modest Return on Capital Employed
Return on capital employed was modest at -1.82% in FY26. Investors can track whether later filings change this ratio, since one quarter of profit does not by itself alter a full-year return on capital.
High Debt Level
Debt is high at 0.45 times total assets in FY26. This is a balance sheet measure that sits apart from the quarter’s profit line, so it remains a point to follow in later filings.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Bharat Parenterals Q2 Results FY27 show consolidated revenue of Rs 136.28 Cr, up 110.89%, and PAT of Rs 11.82 Cr against a year-ago loss. The quarterly results also record Operating Profit of Rs 23.58 Cr. Reading Bharat Parenterals Q2 Results together with later filings gives a fuller view of these consolidated results. Investors should consult a SEBI-registered advisor before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Bharat Parenterals Q2 Results FY27
What are Bharat Parenterals Q2 Results FY27?
Ans. Bharat Parenterals Q2 Results FY27 are the consolidated July to September 2026 quarterly results of Bharat Parenterals, with revenue of Rs 136.28 Cr and a profit of Rs 11.82 Cr, while Financial Highlights lists every line against last year.
What is the results date for Bharat Parenterals Q2 Results FY27?
Ans. Bharat Parenterals Q2 Results FY27 were declared on 29 October 2026 for the July to September 2026 quarter. This results date opens the article, which also confirms these are consolidated results throughout.
What revenue was reported in Bharat Parenterals Q2 Results FY27?
Ans. Bharat Parenterals reported consolidated revenue of Rs 136.28 Cr in the quarter, compared with Rs 64.62 Cr a year earlier. This means the Performance Analysis section shows revenue rising 110.89% YoY.
What net profit was reported in Bharat Parenterals Q2 Results FY27?
Ans. Bharat Parenterals reported net profit of Rs 11.82 Cr in Bharat Parenterals Q2 Results FY27, against a loss of Rs 8.60 Cr last year, so the Key Takeaways section records a swing of Rs 20.42 Cr.
How much YoY growth did revenue show in Bharat Parenterals Q2 Results FY27?
Ans. Revenue showed YoY growth of 110.89% in Bharat Parenterals Q2 Results FY27, rising from Rs 64.62 Cr to Rs 136.28 Cr. Alongside this, the Performance Analysis section sets that growth next to the Operating Profit move.
Did net profit rise or fall in Bharat Parenterals Q2 Results?
Ans. Profit rose in Bharat Parenterals Q2 Results, moving from a loss of Rs 8.60 Cr to Rs 11.82 Cr. Compared with last year, the margin improved to 8.7% from -13.3%, as the Key Business Factors section notes.
What was the Operating Profit in Bharat Parenterals Q2 Results FY27?
Ans. Operating Profit in Bharat Parenterals Q2 Results FY27 was Rs 23.58 Cr on the results date, compared with Rs 0.82 Cr a year earlier, a rise of 2,775.61%. The Performance Analysis section shows it at 17.30% of revenue.
Are Bharat Parenterals Q2 Results consolidated results or standalone results?
Ans. Bharat Parenterals Q2 Results are consolidated results, so every figure covers Bharat Parenterals on a Consolidated basis. Alongside this, the opening section explains how the basis and the results date frame the comparison with last year.
What business factors shaped Bharat Parenterals Q2 Results FY27?
Ans. Revenue growth of 110.9%, a return to a profit of Rs 11.82 Cr and a profit margin of 8.7% shaped Bharat Parenterals Q2 Results FY27. The Key Business Factors section sets out these three items.
What are the key risks after Bharat Parenterals Q2 Results FY27?
Ans. The risks after Bharat Parenterals Q2 Results FY27 are return on equity of -8.36%, return on capital employed of -1.82% and debt of 0.45 times total assets, all for FY26. The Key Risks section explains each one.
What is the outlook after Bharat Parenterals Q2 Results?
Ans. FY27 full-year results will depend on the quarters still to be declared, and Bharat Parenterals Q2 Results cover only July to September 2026. So the FY27 Outlook section treats this quarter as one input.
Where can I find the complete Bharat Parenterals Q2 Results FY27 data?
Ans. The complete figures sit in the Financial Highlights table of this article, while the Univest app and Univest Screener help follow later filings. So readers can return to that table for every line.
